Table 4 Percentage of patients discontinuing anti-TNF first- or subsequent-line biologic therapy and abatacept
| Â | First anti-TNF | Subsequent anti-TNF | Â | ||||
|---|---|---|---|---|---|---|---|
Discontinuation definition | Etanercept (N = 1593) | Adalimumab (N = 1040) | Infliximab (N = 584) | Etanercept (N = 258) | Adalimumab (N = 353) | Infliximab (N = 156) | Abatacept (N = 398) |
60 day gap or non-index biologic start | 49.9% | 52.9% | 39.6% | 52.7% | 63.7% | 45.5% | 53.1% |
180 day gap or non-index biologic start | 36.7% | 42.6% | 33.4% | 43.8% | 56.4% | 41.7% | 18.0% |